ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Elizabeth H.Z. Thompson sold 16,558 shares of the business's stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president directly owned 18,994 shares in the company, valued at approximately $496,313.22. This trade represents a 46.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
ACADIA Pharmaceuticals Stock Performance
ACADIA Pharmaceuticals stock opened at $25.87 on Friday. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 11.76, a PEG ratio of 18.41 and a beta of 0.80. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $28.35. The stock's 50 day moving average price is $23.74 and its two-hundred day moving average price is $23.23.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. During the same quarter in the prior year, the firm earned $0.11 EPS. The business's revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.39 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of ACAD. Farther Finance Advisors LLC lifted its stake in shares of ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 386 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth about $26,000. Transamerica Financial Advisors LLC increased its position in shares of ACADIA Pharmaceuticals by 304.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 1,005 shares in the last quarter. Federated Hermes Inc. increased its position in shares of ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company's stock worth $43,000 after acquiring an additional 1,185 shares in the last quarter. Finally, Leonteq Securities AG acquired a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $52,000. Institutional investors and hedge funds own 96.71% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have weighed in on ACAD shares. Canaccord Genuity Group lifted their price target on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Bank of America reissued a "buy" rating and set a $14.50 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday. Citigroup raised their target price on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, June 29th. Finally, BMO Capital Markets upped their price target on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 21st. Thirteen research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $32.31.
Get Our Latest Stock Report on ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Company Profile
(
Get Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company's flagship product, NUPLAZID® (pimavanserin), received U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
